Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Highlights from the 2025 Symposium of the Collegium Internationale Allergologicum.

The Journal of allergy and clinical immunology·2026
Same author

CD25 expression marks an activated mast cell population in human nasal polyposis.

The Journal of allergy and clinical immunology·2026
Same author

Tuft cells shape airway remodeling by eliciting OXGR1- and SOX9-dependent stem cell programs.

Nature communications·2026
Same author

Platelet-macrophage cooperation drives IL-33-dependent type 2 lung immunopathology in a sex-biased manner.

The Journal of allergy and clinical immunology·2026
Same author

Mast cell-specific CysLT2 receptor signaling inhibits cysteinyl leukotriene-dependent mast cell activation and type 2 allergic lung inflammation.

Cell reports·2025
Same author

Progenitor T cells drive chronic pulmonary type 2 inflammation.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: May 8, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Lipid mediators and allergic diseases.

Laura B Fanning1, Joshua A Boyce

  • 1Brigham and Women's Hospital, Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Jeff and Penny Vinik Center for Allergic Disease Research, Boston, Massachusetts, USA. LFanning@partners.org

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|August 31, 2013
PubMed
Summary

Lipid mediators are key in allergic diseases. Understanding these molecules and their pathways has led to targeted therapies like leukotriene receptor antagonists and 5-lipoxygenase inhibitors.

More Related Videos

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Related Experiment Videos

Last Updated: May 8, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • Lipid mediators are bioactive molecules derived from cell membrane phospholipids.
  • They significantly influence inflammatory and immune responses in various disease states.

Purpose of the Study:

  • To review the fundamental science of lipid mediators.
  • To explore their translational relevance in the pathobiology of allergic diseases.

Main Methods:

  • A comprehensive PubMed search was conducted.
  • Keywords included "lipid mediator," "prostaglandin," "leukotriene," "asthma," and "allergic inflammation."
  • Articles emphasizing clinical and translational aspects of basic science were prioritized.

Main Results:

  • Lipid mediators and their receptors show potential as diagnostic markers.
  • These molecules are crucial in the inflammatory processes underlying allergic conditions.
  • They represent valuable therapeutic targets for managing allergic diseases.

Conclusions:

  • Therapeutic agents targeting lipid mediator pathways, such as cysteinyl leukotriene receptor type 1 antagonists and zileuton, have been successfully developed.
  • Ongoing research into additional receptor agonists and antagonists is advancing.
  • Future pharmacologic treatments for allergic diseases are expected as understanding of these pathways evolves.